Abstract Many studies have been performed to assess the potential utility of natural products as immunomodulatory agents to enhance host responses against infection or to ameliorate immune-based pathologies. To determine whether eriodictyol has immunomodulatory effects and clarify which types of immune effector cells are stimulated in vitro, we investigated the stimulatory effect of eriodictyol on spleen cells isolated from BALB/c mice. Eriodictyol significantly stimulated splenocyte proliferation. However, only B lymphocytes (not T lymphocytes) could be stimulated by eriodictyol in a dose-related manner. Studies assessing potential effect of eriodictyol on innate immunity reported that eriodictyol enhanced significantly the killing activity of natural killer (NK) cells, T lymphocytes, and macrophages. We also demonstrated that eriodictyol inhibited nitric oxide (NO) production and lysosomal enzyme activity in murine peritoneal macrophages cultured ex-vivo, suggesting a potential anti-inflammatory effect in situ. Eriodictyol revealed also a cellular anti-oxidant activity in splenocytes and macrophages. Furthermore, eriodictyol increased catalase activity in spleen cells. From this data, it can be concluded that eriodictyol exhibited an immunomodulatory effect that could be ascribed in part to a cytoprotective effect related to its anti-oxidant activity.
Introduction
The innate immune system constitutes the first line of host defense during infection and so plays a crucial role in early recognition and subsequent triggering of inflammatory responses to pathogens. The adaptive immune system is responsible for eliminating pathogens primarily through generation of immunological memory. A healthy state is believed based on a fine-tuning of various humoral and cellular factors that help regulate immunoregulatory mechanisms. Inappropriate immunity is a common etiology in an ever-growing array of pathological processes including cancers, allergies, and a variety of autoimmune disorders (Cherng et al. 2007 ). Control of these diseases by immunotherapies has two objectives: development of immunity by stimulation of the host immune system (immunostimulation) and suppression of undesired immune reactions. While pharmacies are replete with both immunostimulants and immunosuppressants, nevertheless, the search for better agents exerting these activities with few side effects remains a major interest of investigators around the world.
Medicinal plants are rich sources of substances that are claimed to impact immunity and impart minimal side effects (Sharififar et al. 2009 ). Flavonoids are polyphenolic compounds that impart significant anti-inflammatory, anti-tumor, and anti-oxidant effects (Hodek et al. 2002) . Eriodictyol, a tetra-hydroxy-flavanone, has anti-oxidant and antiinflammatory activities (Clavin et al. 2007; Rossato et al. 2011) . Eriodictyol is also capable to protect human adult pigment epithelial (ARPE-19) cells against oxidative stress (Johnson et al. 2009) . However, few studies have investigated the immunomodulatory effect of eriodictyol. The aim of the study is to examine the immunomodulatory, anti-inflammatory, and the anti-oxidant activities of eriodictyol in splenocytes and macrophages.
Material and methods

Chemicals
Eriodictyol was purchased from Sigma-Aldrich (Canada Ltd). Penicillin, streptomycin, RPMI-1640 medium, phosphatebuffered saline (PBS, pH 7.4), and fetal bovine serum were purchased from Gibco by Life Technology, France. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) was procured from Euromedex (Mundolsheim, France). Dimethyl sulfoxide (DMSO) was purchased from Sigma-Aldrich (St. Q uentin Fa llavier, Fran ce). Lipopolysaccharide (LPS, rough strain, E. coli EH100) was purchased from Sigma (Hamburg, Germany), and lectin (from Phytolacca americana, pokeweed) was from Sigma-Aldrich (St. Louis, MO, USA). Triton X-100 was purchased from Biomatik Corporation (Cambridge, UK). p-Nitrophenyl phosphate (p-NPP) was from AppliChem (GmbH, Darmstadt, Germany). 2,7-dichlorofluorescindiacetate (DCFH-DA) was procured from Fluka (Steinheim, Germany). 2,2′-Azobis(2-amidinopropane) dihydrochloride (ABAP) was from SigmaAldrich (Steinheim, Germany).
Animals
Male BALB/c mice between 6 and 8 weeks old (weight, 20.0 ± 2.0 g) were purchased from the Pasteur Institute, Tunis, Tunisia. Animals were housed in a dedicated room in individually ventilated cages where temperature and relative humidity were set at 22 ± 6°C and 40 ± 10 %, respectively. Artificial lighting provided a 24-h cycle of 12-h light/12-h dark, and food and water were available ad libitum. All experiments were performed in accordance with the guidelines for the care and use of laboratory animals as published by the US National Institute of Health. All experiments received the explicit approval of the Ethics Animal Committee in Tunisia.
Cell proliferation assay
Assays of lymphocyte proliferation were performed according to the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] method outlined by Mosmann (1983) . Briefly, mice were euthanized and their spleens were aseptically isolated. Each spleen was minced with sterile forceps and the liberated splenocytes then centrifuged (1500 rpm, 10 min). To remove any red blood cells present, the cells were resuspended in lysing buffer (144 mM NH 4 Cl in 1.7 mM Tris base, pH 7.4) and placed on ice for 10 min. The cells were then washed twice with phosphate-buffered saline (PBS, pH 7.4) and then resuspended in complete RPMI (RPMI-1640 containing 10 % FBS and 10 μg ml −1 penicillin-streptomycin).
For this assay, splenocytes in complete RPMI (5 × 10 6 cells/ ml; 100 μl aliquot/well) were pre-incubated (37°C, 5 % CO 2 ) in 96-well plates for 24 h before addition (20 μl/well) of LPS as mitogen or lectin as weak mitogen, each to achieve final concentration in well of 5 μg/ml and the tested compound. For use, LPS, lectin, or the tested compound were all diluted from stocks in complete RPMI. Cells were then incubated for an additional 48 h before the plates were centrifuged at 1500 rpm for 10 min. The cell pellet in each well was resuspended in 40 μl MTT (5 mg/ml RPMI) solution, and the plate was incubated for an additional 2 h at 37°C. The plate was then centrifuged again, the MTT in each well was removed, and 100 μl dimethyl sulfoxide (98 % DMSO; Sigma-Aldrich, St. Quentin Fallavier, France) was added. The absorbance in each well was measured at 570 nm in a microplate reader (Thermo Scientific, Vantaa, Finland) and the percentage of proliferation ultimately calculated using the following: proliferation (%) = 100 × (OD sample − OD control) / OD control.
Activity of NK cells
Natural killer (NK) cell activity was measured as previously described (Sarangi et al. 2006) . In brief, the spleens above were used as the source of effector cells; isolated splenocytes were seeded into 96-well plates at 5 × 10 6 cells/ml. The cells were then stimulated with different concentrations of eriodictyol for 24 h. To eliminate direct effects of eriodictyol on target cells, the spleens were washed once with RPMI-1640 and then target K562 cells (5 × 10 4 cells/ml; yielding a 100:1 expected effector-target ratio) were added to each well in 100 μl aliquots. The plates were then incubated for 4 h at 37°C. An aliquot (40 μl) of MTT solution (5 mg/ml) was then added to each well and the plate incubated a further 2 h. Absorbance in each well was measured at 570 nm in the microplate reader. Three kinds of control measurements were taken: target cell control, blank control, and effector cell control. NK cell activity was calculated as follows: NK activity (%) = 100 % × (ODT − (ODS − ODE)) / ODT, where ODT = optical density value of target cell control, ODS = optical density value of test samples, and ODE = optical density value of effector cell control.
Assay of CTL activity
Cell-mediated cytotoxicity was performed using MTT assay. Splenocytes in complete RPMI-1640 (5 × 10 6 effector cells/ ml; 100 μl aliquot/well) were pre-incubated in 96-well plates for 24 h and then treated with different concentrations of eriodictyol for 24 h. Thereafter, target B16-F10 melanoma cells (5 × 10 4 target cells/ml; yielding a 100:1 expected effector-target ratio) were added to each well in 100 μl aliquots. The plates were then incubated for 24 h at 37°C prior to addition of MTT. Three kinds of control measurements were performed: target cell control, blank control, and effector cell control. Cytotoxic T lymphocyte (CTL) cell activity was calculated as follows: % activity = 100 % × (ODT − (ODS − ODE)) / ODT, where ODT = optical density value of target cell control, ODS = value of test sample-treated cells, and ODE = optical density value of effector cell control.
Nitrite release determination
Peritoneal macrophages were obtained from the peritoneal cavity of other mice after sacrifice. Peritoneal cells were obtained after intraperitoneal injection of 4 ml sterile PBS, massaging of the peritoneum, and drawing back of the fluid (≈4 ml) into the syringe. The obtained cells were washed twice and resuspended in complete RPMI-1640 medium.
The amount of nitric oxide (NO) released by macrophages was measured by determining the amounts of accumulated nitrite (NO 2 _ ) in cell-free supernatants via the Griess reaction (Green et al. 1982) . In brief, cells were incubated for 48 h at 37°C in the presence of increasing doses of eriodictyol. Nitrite was then measured by adding 100 μl of Griess reagent (1 % sulfanilamide and 0.1 % naphthylenediamine in 5 % phosphoric acid) to 100 μl of harvested culture supernatant. The optical density at 570 nm (OD570) was then measured in the microplate reader. NO concentrations were calculated by comparison with the OD570 of a standard solution of sodium nitrite diluted in culture medium and placed in parallel wells in the assay plates.
Assessment of lysosomal activity
Lysosomal enzyme activity (reflected by acid phosphatase [AP] activity) in the macrophages was measured as previously described by Manosroi et al. (2005) . Macrophages (100 μl aliquot of 3 × 10 6 cells/ml) were seeded into flat-bottom 96-well plates, treated with different doses of eriodictyol, and incubated at 37°C for 48 h. The medium was then removed, and 20 μl of 0.1 % Triton X-100 (Sigma, St. Louis, MO), 10 μl of 100 mM p-NPP solution (Sigma), and 50 μl of 0.1 M citrate buffer (pH 5.0) were added to each well. The plate was then incubated for 30 min at 37°C before 150 μl 0.2 M borate buffer (pH 9.8) was added to each well. The absorbance in each well was then measured at 405 nm in the plate reader. The percentage lysosomal enzyme activity in treated culture cells relative to that in control cells was calculated as lysosomal enzyme activity (%) = 100 × (OD sample − OD control) / OD control.
In vitro MMC assay
Macrophage-mediated cytotoxicity (MMC) was performed using the MTT assay. The macrophages (1.5 × 10 5 cells/well) were pre-incubated in 96-well plate for 2 h at 37°C and then treated with different concentrations of eriodictyol for 24 h at 37°C. Thereafter, target B16-F10 melanoma cells (10 4 cells/ well; yielding a 15:1 expected effector-target ratio) were added to each well in 100 μl aliquots. Cells were then incubated at 37°C for an additional 24 h. Three kinds of control measurements were taken: target cell control, blank control, and effector cell control. Macrophage-mediated cytotoxicity (MMC) activity was calculated as follows: MMC (%) = 100 % × (ODT − (ODS − ODE)) / ODT, where ODT = optical density value of target cell control, ODS = optical density value of test sample-treated cells, and ODE = optical density value of effector cell control.
CAA assay
A cellular anti-oxidant activity (CAA) assay (Wolfe and Liu 2007) was used to measure anti-oxidant potentials of the tested molecule, eriodictyol. Splenocytes and macrophages were seeded (in 100 μl PBS) separately at a density of 5 × 10 5 and 6 × 10 4 cells/well, respectively, in 96-well microplates. Triplicate wells were then treated with 10 μl of eriodictyol (6.25, 12.5, 25, and 50 μM) along with 5 μl of 25 μM 2′,7′-dichlorofluorescindiacetate (DCFH-DA; Fluka, Steinheim, Germany). After 1-h incubation at 37°C, 100 μl of 1.2 mM 2,2′-azobis(2-amidinopropane)dihydrochloride (ABAP; Sigma-Aldrich, Steinheim, Germany) in PBS was provided to each well. Here, DCFH-DA is taken up by cells and deacetylated to 2′, 7′-dichlorofluorescein (DCFH). Peroxyl radicals generated from ABAP lead to oxidation of DCFH to fluorescent dichlorofluorescein (DCF). Accordingly, cells treated with a compound that has any anti-oxidant activity should have lower fluorescence compared to untreated cells. Fluorescence in each well was evaluated at 5-min intervals over 1 h using a BioTek fluorescence microplate reader (Winooski, VT) with 538-nm emission and 485-nm excitation filters. Each plate included triplicate control and blank wells: control wells contained cells treated with DCFH-DA and ABAP; blank wells contained cells with PBS and without DCFH-DA and ABAP. Fluorescence values for blank samples and initial fluorescence values were subtracted from sample values. The area under fluorescence vs. time curve was integrated at each time point to calculate the CAA units using CAA unit = 100 − (∫SA ⁄ ∫CA) × 100, where ∫SA is the integrated area under the sample fluorescence versus time curve and ∫CA is the integrated area from the control curve.
Determination of catalase activity
Catalase activity in the spleen cells was measured by spectrophotometry at 240 nm, according to Kang et al. (2006) . Spleen cells were treated with various concentrations of eriodictyol for 1 h. The harvested cells were suspended in 10 mM phosphate buffer (pH 7.5) and then lysed on ice by sonication twice for 15 s. Triton X-100 (1 %) was then added to the lysates and was incubated for 10 min on ice. The lysates were centrifuged at 5000g for 30 min at 4°C to remove the cellular debris. Fifty microliters of lysates was added in the quartz cuvette containing 50 mM phosphate buffer (pH = 7) and 100 mM (v/v) H 2 O 2 . The activity of the catalase was calculated using the molar extinction coefficient (0.04 mM −1 /cm). Results were expressed as micromoles of H 2 O 2 per minute per milligram of protein.
Statistical analysis
All data were expressed as mean (±SD) and compared using a Student's t test. Statistical significance was assigned at p value <0.05.
Results
Effects of eriodictyol on splenocyte proliferation
To test whether eriodictyol promoted or inhibited cell proliferation, splenocytes were isolated and cultured with tested compound + the mitogen LPS or with tested compound + lectin (a weak mitogen). Analysis of lymphocyte proliferation in response to eriodictyol exposure showed a dose-dependent increase of lymphocyte proliferation incubated both with eriodictyol and lipopolysaccharide (LPS). Whereas, when incubated with lectin and eriodictyol, lymphocyte proliferation is not affected (Fig. 1a, b) .
Effects on NK cell activity
Measures of the cytotoxic activity of splenic NK cells against NK-sensitive tumor cells (i.e., K562 cell line) revealed that, as compared with the control (medium) vehicle, eriodictyol at different concentrations (5, 10, and 20 μM) significantly enhanced NK cell activity. Eriodictyol increases the activity of these cells from 20 % (untreated cells) to 62 % (in presence of 20 μM of eriodictyol) (Fig. 2) .
Effects on CTL activity
The data indicate that splenocyte CTL activity increased remarkably when cells were treated with eriodictyol in a doserelated manner. The cytotoxicity of lymphocytes toward B16-F10 melanoma cells reached 55 % when incubated with 20 μM of eriodictyol (Fig. 3) .
Effects on macrophage NO production
The effect of eriodictyol on macrophage NO release is reported in Fig. 4 . LPS (5 μg/ml) resulted in the production of ≥56.3 μM NO. This induction was inhibited by eriodictyol treatment in a dose-related manner. In fact, NO production was reduced to 31.8 μM by treatment with 20 μM eriodictyol.
Effects on macrophage lysosomal activity
As shown in Fig. 5 , eriodictyol decreased markedly macrophage lysosomal activity. 
Effects on MMC
Macrophages treated with eriodictyol reduced the proliferation of B16-F10 melanoma cells more strongly than untreated macrophages. Therefore, eriodictyol treatment stimulated anti-melanoma activity in macrophages in a dose-related manner (Fig. 6 ).
Eriodictyol exhibited anti-oxidant activity
The CAA assay was used here to quantitatively evaluate the anti-oxidant activity of eriodictyol in splenocytes and macrophages. The results clearly indicated that the eriodictyol should be absorbed into the cells and exert anti-oxidant activity. Production of fluorescence by ABAP-mediated oxidation was reduced in a dose-related manner (relative to values for untreated control cells) by eriodictyol over the test range of 6.25 to 50 μM (Fig. 7) . The mean effective concentrations (EC 50 ) of eriodictyol were 13 and 14 μM in splenocytes and macrophages, respectively (Fig. 8 ).
Eriodictyol stimulated catalase activity
Catalase enzyme is an endogenous anti-oxidant that can protect cells against adverse effects of reactive oxygen species (ROS). Level of catalase can indicate the magnitude of oxidative stress that occurs. Our results demonstrated that eriodictyol induced a marked increase in catalase activity. Catalase activity increased from 151 μmol/min/mg protein (Fig. 9 ).
Discussion
The immune system is the ultimate defense against infectious diseases, tumor, and cancer growth. Modulation of immune response through stimulation or suppression may help in maintaining a disease-free state. For the above reasons, we focused on how eriodictyol can modulate lymphocyte and macrophage responses as well as other inflammatory mediators. The effects of eriodictyol on both LPS-and lectinstimulated cell proliferation were analyzed. Lectin stimulates T cells that are involved in cell-mediated immunity, while LPS acts on B cells that are responsible for humoral immune responses (Harizi et al. 2011) . Eriodictyol upregulated only LPS-induced cell proliferation. This result suggested potential synergistic effect of eriodictyol upon LPS. By enhancing LPSinduced cell proliferation, eriodictyol might act as modulator of B cell function and, consequently, of humoral immune response in situ. Whereas, since lectin-induced splenocyte proliferation was not affected by eriodictyol, we concluded that the cellular immune response was not involved. Natural killer (NK) cells are a component of the innate immune system and have the ability to both lyse target cells and provide an early source of immunoregulatory cytokines (Caligiuri 2008) . NK cells are able to recognize and to destroy targets that have lost expression of MHC class I molecules (Ljunggren and Karre 1990) . Flavonoids can stimulate NK cytotoxic activity. Myricetin and quercetin enhanced the activity of NK in a dose-dependent manner (Lindqvist et al. 2014) . Resveratrol increased the cytotoxic activity of NK cells in vivo (Lu and Chen 2010) . Furthermore, NK cell-induced K562 target cell death was increased in the presence of luteolin (Ismail et al. 2012 ). The present study is the first to show that in vitro NK cell activity can be affected by eriodictyol.
Cytotoxic T lymphocytes (CTLs) play an important role in protecting against viral infections and cancer and rejection of organ transplants. CTLs constitute the major antitumor effector population and are recognized for their involvement in host resistance against tumor growth and dissemination (Whiteside and Herberman 1995) . In this report, we have demonstrated that eriodictyol treatment increases the activity of ex vivo splenic CTL. The flavonoid, genistein, modulated the immune system and increased the activities of cytotoxic T and NK cells against B16-F10 cancer cells (Guo et al. 2001) .
Macrophages are an important component in innate immunity. They function primarily as phagocytic cells and are capable of phagocytosing pathogenic organisms (Kovacs et al. 2009 ). In addition, activated macrophages generate large amount of NO from arginine and oxygen by various nitric oxide synthases (NOS) and by reduction of inorganic nitrate (Manosroi et al. 2005) . NO is released by bacterial infection or inflammatory responses and is toxic to bacteria and other human pathogens. Excessive amounts of NO react with superoxide to produce peroxinitrite. Peroxynitrite is a damaging oxidant and nitrating agent, since it can damage a wide array MacMicking et al. 1997) , our experiment revealed that eriodictyol inhibited NO synthesis, by peritoneal macrophages. Similarly, eriodictyol downregulated NO formation (Huang et al. 2009 ). Moreover, eriodictyol reduced the NO production in LPS-stimulated Raw 264.7 macrophages (Lee 2011) . The presence of OH groups at positions 5, 7, 3′, and 4′, together with the double bond in the B ring, is involved in the high anti-inflammatory effect of flavonoids (Comalada et al. 2006) . The presence of two hydroxyl groups at the 3′and 4′ positions of the B ring of eriodictyol could explain its antiinflammatory activity. Macrophages carry out their non-specific defense function at the elimination stage of the phagocytic process by activating the lysosomal phosphatase in the cytosolic vesicles (Nworu et al. 2010) . The activity of lysosomal enzymes like alkaline phosphatase increased markedly during inflammation process and thus caused tissue damages (Chayen et al. 1970 ). The present study showed that eriodictyol decreased lysosomal phosphatase activity, revealing its anti-inflammatory potential.
Similarly, eriodictyol exhibited an anti-inflammatory effect in lipopolysaccharide (LPS)-induced acute lung injury in a mouse model, by regulating the Nrf2 pathway and inhibiting the expression of inflammatory cytokines (TNF-α, IL-6, IL-1β, and MIP-2) in macrophages (Zhu et al. 2015) . Furthermore, eriodictyol decreased the oxidative stress level by reducing the accumulation of H 2 O 2 , OH·, and MDA in the lung tissues. Another study conducted in vivo showed that eriodictyol attenuated cisplatin-induced kidney injury by inhibiting oxidative stress and inflammation. In fact, eriodictyol treatment reduced the production of TNF-α, and IL-1β in kidney tissues induced by cisplatin and also upregulated the activities of superoxide dismutase, catalase, and glutathione peroxidase (Li et al. 2016) . The enzymes cyclooxygenase-1 (COX-l), cyclooxygenase-2(COX-2), and xanthine oxidase (XO) play key roles in the pathology of inflammatory diseases. Eriodictyol had an inhibitory effect on COX-1 and COX-2 and had a suppressive effect on XO activity, which confirm its anti-inflammatory and its antioxidant potencies .
Macrophages can also be stimulated, both in vivo and in vitro, to exert cytotoxic activity against tumor cells. Their antitumor potential is often more efficient than other kinds of immunocompetent cells (Dumont et al. 1985) . In fact, these cells play a complex role in tumor biology; their presence within a tumor can either correlate with tumor destruction or tumor growth. To become tumoricidal in vitro, macrophages must be stimulated in two ways. First, cytokines prime the macrophages, while secondary signals allow the macrophage to kill the tumor cell (Russell et al. 1977) . Killing of target cells can be mediated through direct contact or through the production of soluble factors, or both, and the effectiveness of the mechanisms of killing employed by the macrophages is dependent on the target type and the pathway of macrophage activation (Keller et al. 1990) . In this study, eriodictyol treatment stimulates macrophage-mediated cytotoxicity, in a dosedependent manner. In fact, the flavanone, naringenin, enhanced macrophage-mediated cytotoxicity activity against Ehrlich ascite tumor cells (Orsolić and Basić 2005) .
ROS are free radicals that contain an oxygen atom and are formed as natural by-products of the normal metabolism of oxygen and have important roles in cell signaling (Rada and Leto 2008) . Over-production of ROS/inadequate anti-oxidant defenses are associated with the pathogenesis of chronic inflammatory diseases. Our results clearly show that eriodictyol prevented ABAP-induced DCFH oxidation in splenocytes and macrophages in a dose-related manner and increased the activity of catalase, one of the most effective anti-oxidant enzymes that are produced naturally in the body to prevent free radical damage. In fact, eriodictyol contains numerous double bonds and hydroxyl groups that can donate electrons through resonance to stabilize the free radicals. Furthermore, eriodictyol was comparable with luteolin, quercetin, and taxifolin, as efficient anti-oxidants in protecting retinal cells against oxidative stress (Areias et al. 2001) . Oxidative stress plays a key role in the pathogenesis of various serious diseases such as cardiovascular diseases. Eriodictyol upregulated oxygenase 1 (HO-1) , a phase II detoxifying enzyme, in endothelial cells (HUVECs) through extracellular-regulated kinase (ERK)/nuclear factor erythroid 2-related factor 2 (Nrf2)/anti-oxidant response element (ARE) signaling pathways (Lee et al. 2015) . Furthermore, eriodictyol treatment protected these cells against hydrogen peroxideinduced cell death.
Diverse anti-inflammatory drugs have a radical-scavenging mechanism as part of their activity. Free radicals propagate inflammation by causing release of inflammatory cytokines, such as interleukin-1, tumor necrosis factor-α, and interferon-γ, that stimulate recruitment of additional neutrophils and macrophages. Neutralization of free radicals by antioxidant agents can attenuate inflammation (Delaporte et al. 2002) . Thus, as eriodictyol exhibited a highly anti-oxidant potential, we believe that it may be responsible at least partly for its anti-inflammatory and immunomodulatory potentials.
Based on the results presented here, we conclude that eriodictyol has anti-oxidant properties as well as immunomodulating effects upon splenocytes, NK cells, and macrophages. Further studies on the specific mechanism of eriodictyol, in order to establish its therapeutic potential for the prevention of immune diseases, are required.
